Literature DB >> 21255804

MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer.

Katia R M Leite1, Alberto Tomiyama, Sabrina T Reis, Juliana M Sousa-Canavez, Adriana Sañudo, Marcos F Dall'Oglio, Luiz H Camara-Lopes, Miguel Srougi.   

Abstract

PURPOSE: Abnormal miRNA expression has emerged as crucial factors in carcinogenesis and is important in the comprehension of prostate cancer behavior. We determined the correlation of miRNA expression profiles with prostate cancer progression.
MATERIALS AND METHODS: We studied frozen specimens from 49 patients treated for prostate cancer with radical prostatectomy. We intentionally chose 28 men without and 21 with biochemical recurrence, defined as prostate specific antigen greater than 0.2 ng/ml. The expression of 14 miRNAs was determined by quantitative reverse transcriptase-polymerase chain reaction. All radical prostatectomy specimens were studied in toto to determine tumor volume, Gleason score and 2002 TNM pathological stage. Benign prostate tissue from benign prostatic hyperplasia served as a control.
RESULTS: Four miRNAs were related to tumor recurrence. Using the Cox regression test the risk of recurrence was 3.0, 3.3, 2.7 and 3.4 for high levels of miR-100, miR-145, miR-191 and miR-let7c, respectively. When considering statistically significant clinical variables on univariate analysis of biochemical-free survival, prostate specific antigen and tumor volume, results revealed that miR-100 and tumor volume were independently related to tumor recurrence.
CONCLUSIONS: A high level of miR-100 is related to biochemical recurrence of localized prostate cancer in patients treated with radical prostatectomy. The role of miR-100 during carcinogenesis must be resolved in future studies to better understand the molecular pathways in which miR-100 is involved. This may open the possibility of using it as a prognostic marker and inspire the development of a target drug.
Copyright © 2011 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255804     DOI: 10.1016/j.juro.2010.10.035

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  37 in total

1.  Role of miR-100 in the radioresistance of colorectal cancer cells.

Authors:  Xiao-Dong Yang; Xiao-Hui Xu; Shu-Yu Zhang; Yong Wu; Chun-Gen Xing; Gan Ru; Hong-Tao Xu; Jian-Ping Cao
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 2.  Potential role of miR-100 in cancer diagnosis, prognosis, and therapy.

Authors:  Chu Qin; Ru-Yi Huang; Zhao-Xia Wang
Journal:  Tumour Biol       Date:  2015-03-05

Review 3.  MicroRNAs as putative mediators of treatment response in prostate cancer.

Authors:  Fardod O'Kelly; Laure Marignol; Armelle Meunier; Thomas H Lynch; Antoinette S Perry; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2012-05-22       Impact factor: 14.432

4.  Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer.

Authors:  Jing Shen; Gregory W Hruby; James M McKiernan; Irina Gurvich; Michael Jeffrey Lipsky; Mitchell C Benson; Regina M Santella
Journal:  Prostate       Date:  2012-02-01       Impact factor: 4.104

5.  Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma.

Authors:  Yinghua He; Ying Cui; Wei Wang; Jun Gu; Shicheng Guo; Kelong Ma; Xiaoying Luo
Journal:  Neoplasia       Date:  2011-09       Impact factor: 5.715

6.  Refute the conclusion made by Jie et al. in "prognostic role of microRNA-100 in various carcinomas: evidence from six studies".

Authors:  Dali Chen; Yubin Zhou; Heng Du; Guowei Che
Journal:  Tumour Biol       Date:  2014-06-06

Review 7.  An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.

Authors:  R G Bristow; A Berlin; A Dal Pra
Journal:  Br J Radiol       Date:  2014-02-03       Impact factor: 3.039

Review 8.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

9.  MicroRNA-100 regulates IGF1-receptor expression in metastatic pancreatic cancer cells.

Authors:  J S Huang; M E Egger; W E Grizzle; L R McNally
Journal:  Biotech Histochem       Date:  2013-02-04       Impact factor: 1.718

10.  miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases.

Authors:  Ernest K Amankwah; Evelyn Anegbe; Hyun Park; Julio Pow-Sang; Ardeshir Hakam; Jong Y Park
Journal:  Asian J Androl       Date:  2013-01-28       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.